Galera Therapeutics 8/14/2024 Earnings Report

Galera Therapeutics EPS Results

• Actual EPS: -$0.07
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Galera Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Galera Therapeutics Announcement Details

• Date: 8/14/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Galera Therapeutics (NASDAQ:GRTX) is a clinical‐stage biopharmaceutical company focused on the discovery and development of small‐molecule therapies that modulate reactive oxygen species (ROS) in order to address serious side effects associated with radiation therapy and ongoing inflammatory diseases. The company’s proprietary approach leverages a class of antioxidants designed to mimic natural cellular defense enzymes, aiming to protect healthy tissues without diminishing the therapeutic impact of radiation on tumor cells.

The company’s lead candidate, avasopasem manganese, is a novel dismutase mimetic in late‐stage clinical development for the prevention of severe oral mucositis in patients receiving high‐dose radiation and chemotherapy for head and neck cancers. Beyond oncology, Galera is advancing additional pipeline programs that target organ‐specific toxicities arising from radiation exposure and acute inflammatory conditions, seeking to expand its portfolio into supportive care and related therapeutic areas.

Established in 2017 as a spin-out from a leading academic research center, Galera Therapeutics is headquartered in Research Triangle Park, North Carolina, with additional research operations in the United Kingdom. The company collaborates with academic institutions, contract research organizations and clinical sites across North America and Europe to accelerate its translational research efforts and global clinical trials.

Galera’s senior management team comprises seasoned executives in pharmaceutical development, clinical operations and regulatory affairs. The leadership group is supported by a board of directors and scientific advisors with deep expertise in oncology, chemistry and immunology, underscoring the company’s commitment to advancing novel therapeutic solutions for patients undergoing radiation and inflammatory disease treatments.